Clinical trials: Rendu Osler Disease
Hereditary Haemorrhagic Telangiectasia, PFO - Patent Foramen Ovale
Non-Invasive Detection of Pulmonary Right-to-Left Shunts Using the SONAS Ultrasound Device
The goal of this clinical trial is to learn how well the SONAS ultrasound device can detect right-to-left shunts of adults with hereditary hemorrhagic telangiectasia (HHT) who are already scheduled for a contrast bubble…
- Conditions
- Hereditary Haemorrhagic Telangiectasia, PFO - Patent Foramen Ovale, Pulmonary Arteriovenous Malformation
- Trial name
- SONAS (NCT07414446)
- Testing
- Transcranial Ultrasound Device
- Where
- Netherlands
- Volunteers
- 40 people
- Sponsor
- St. Antonius Hospital
Hereditary Hemorrhagic Telangiectasia, Ectasia
Phase II Pilot Study of Octreotide, a Somatostatin Octapeptide Analog, for Gastrointestinal Hemorrhage in Hormone-Refractory Hereditary Hemorrhagic Telangiectasia and Senile Ectasia
OBJECTIVES: I. Evaluate the efficacy of octreotide, a somatostatin octapeptide analog, in decreasing gastrointestinal bleeding in patients with hormone-refractory hereditary hemorrhagic telangiectasia or senile ectasia.
- Trial name
- NCT00004327
- Testing
- octreotide
- Volunteers
- 8 people
- Sponsor
- National Center for Research Resources (NCRR)
Hereditary Hemorrhagic Telangiectasia
Timolol Gel for Epistaxis in Hereditary Hemorrhagic Telangiectasia
This study is a double-blinded, randomized controlled trial to evaluate the efficacy of an intranasal topical timolol gel in the care for epistaxis in adults with hereditary hemorrhagic telangiectasia.
- Trial name
- ETIC-HHT (NCT04139018)
- Testing
- Timolol Gel
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Washington University School of Medicine
Hereditary Hemorrhagic Telangiectasia
Development of a Quality of Life Measurement Scale in Hereditary Haemorrhagic Telangiectasia (HHT) Disease.
Hereditary Haemorrhagic Telangiectasia (HHT) is a rare inherited genetic disease of autosomal dominant inheritance with a prevalence of 1/6000.
- Trial name
- ELECT-RO (NCT03695874)
- Testing
- Phase 1 : fill out 1 scale, Phase 2 : fill out 1 scale and 4 questionnaires
- Where
- France
- Volunteers
- 643 people
- Sponsor
- Hospices Civils de Lyon
Hereditary Haemorrhagic Telangiectasia (HHT)
Diet and Hereditary Haemorrhagic Telangiectasia
Hereditary Haemorrhagic Telangiectasia (HHT) affects 1 in 5,000 people. The purpose of this study is to provide data regarding the diet and nosebleed frequency using a questionnaire. This will be filled in by people with HHT.
- Trial name
- NCT01692015
- Testing
- Questionnaire on dietary history, Questionnaire on nosebleed severity, One week food diary generated by weighing foods
- Where
- United Kingdom
- Volunteers
- 50 people
- Sponsor
- Imperial College London
Hereditary Hemorrhagic Telangiectasia
Phase III Randomized, Placebo-Controlled, Crossover Study of Soy Protein Isolate for Hereditary Hemorrhagic Telangiectasia
OBJECTIVES: I. Evaluate migraine prophylaxis with soy protein isolate in patients with hereditary hemorrhagic telangiectasia. II.
- Trial name
- NCT00004654
- Testing
- soy protein isolate
- Volunteers
- 60 people
- Sponsor
- National Center for Research Resources (NCRR)
Hereditary Hemorrhagic Telangiectasia (HHT)
Frequency of Common Medical Conditions in People With and Without HHT
Hereditary Hemorrhagic Telangiectasia (HHT) affects 1 in 5,000 people. The purpose of this study is to provide data regarding the frequency of common health conditions and the tolerability of therapies in HHT by using a…
- Trial name
- NCT02464644
- Testing
- Questionnaire
- Where
- United Kingdom
- Volunteers
- 2,174 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Hereditary Hemorrhagic Telangiectasia
A Trial to Assess the Efficacy and Safety of Engasertib in Participants With Moderate to Severe Hereditary Hemorrhagic Telangiectasia (HHT)
The primary objective of this trial is to assess the efficacy of engasertib 40 mg once daily (QD) in reducing the frequency of epistaxis compared to placebo QD during 28 weeks of double-blind treatment in participants with…
- Trial name
- NCT07743671
- Testing
- Engasertib
- Where
- 4 sites in United States
- Volunteers
- 240 people
- Sponsor
- Vaderis Therapeutics AG
Telangiectasia, Hereditary Hemorrhagic
Efficacy of Nintedanib for Treatment of Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) Patients
Patients affected by hereditary hemorrhagic telangiectasia (HHT) very often suffer from recurrent nosebleeds called epistaxis. There is no treatment currently available to reduce the frequency or severity of epistaxis.
- Trial name
- EPISTOP (NCT04976036)
- Testing
- Nintedanib
- Where
- 3 sites in France, Switzerland
- Volunteers
- 48 people
- Sponsor
- Dr. Romain Lazor
Hereditary Haemorrhagic Telangiectasia, Pulmonary Arteriovenous Malformation
Pulmonary Arteriovenous Malformations (PAVMs) in Hereditary Haemorrhagic Telangiectasia (HHT)
Computed tomography (CT) is the modality of choice to characterize pulmonary arteriovenous malformations (PAVMs) in patients with hereditary haemorrhagic telangiectasia (HHT).
- Conditions
- Hereditary Haemorrhagic Telangiectasia, Pulmonary Arteriovenous Malformation, Cerebral Disorder
- Trial name
- PAVM (NCT03940014)
- Testing
- Data collection from standard follow up
- Volunteers
- 170 people
- Sponsor
- Hospices Civils de Lyon
Hereditary Hemorrhagic Telangiectasia, HHT
CHORUS - Comprehensive HHT Outcomes Registry of the United States (Formerly OUR HHT Registry)
The goal of this study is to better understand HHT, the symptoms and complications it causes ("outcomes") and how the disease impacts people's lives.
- Conditions
- Hereditary Hemorrhagic Telangiectasia, HHT, Arteriovenous Malformation of Brain
- Trial name
- NCT04150822
- Testing
- Registry and Saliva sample
- Where
- Canada
- Volunteers
- 296 people
- Sponsor
- Unity Health Toronto
Rendu Osler Disease
Calcium-phosphate Complications Induced by IV Iron Supplementation in Patients With Rendu-Osler Disease
Hypophosphatemia induced by treatments with injectable iron is a frequent side effect already reported during marketing. Situations of osteomalacia secondary to these hypophosphatemias are rarer and reported in the form of case…
- Trial name
- OS-LERETRO (NCT05544669)
- Where
- France
- Volunteers
- 220 people
- Sponsor
- University Hospital, Strasbourg, France
Hereditary Haemorrhagic Telangiectasia (HHT)
Immunmodulation in Patients With HHT
Hereditary haemorrhagic telangiectasia (HHT), also known as Rendu-Osler-Weber syndrome, is an inherited multisystemic disorder. Literature suggests that HHT is often associated with higher frequency of infectious diseases.
- Trial name
- NCT02983253
- Testing
- blood sample
- Where
- Germany
- Volunteers
- 124 people, healthy volunteers welcome
- Sponsor
- University Hospital, Essen
Hereditary Hemorrhagic Telangiectasia (HHT)
Assess Safety and Efficacy of VAD044 in HHT Patients
Part I: The purpose of this Phase 1b proof of concept study, randomised, placebo controlled, double blind, multicentre study is to asssess safety and efficacy of 2 doses of VAD044 in adult HHT patients.
- Trial name
- NCT05406362
- Testing
- VAD044 Part I, VAD044 Part II
- Where
- 7 sites in United States, Belgium and 4 more
- Volunteers
- 75 people
- Sponsor
- Vaderis Therapeutics AG
Telangiectasia, Hereditary Hemorrhagic
Studies of Hereditary Hemorrhagic Telangiectasia
OBJECTIVES: I. Examine screening modalities for pulmonary vascular arteriovenous malformation (PAVM) in individuals with endoglin mutations. II.
- Trial name
- NCT00004648
- Volunteers
- 65 people
- Sponsor
- National Center for Research Resources (NCRR)
Hereditary Hemorrhagic Telangiectasia (HHT)
Description of the Impact of Symptoms on Quality of Life in HHT Disease: DISQUO
In 2017, the ELECT-RO study led, firstly, to the creation of a tool to measure quality of life (QoL) specific to HHT (hereditary haemorrhagic telangiectasia disease), QoL-HHT, based on patients' experiences, their representations…
- Trial name
- DISQUO (NCT07191639)
- Testing
- completion of the QOL-HHT questionnaire
- Where
- France
- Volunteers
- 185 people
- Sponsor
- Hospices Civils de Lyon
Hereditary Haemorrhagic Telangiectasia (HHT)
Symptoms and Treatment Results in Hereditary Hemorrhagic Telangiectasia
Hereditary haemorrhagic telangiectasia (HHT), also known as Rendu-Osler-Weber syndrome, is an inherited multisystemic disorder with recurrent epistaxis, mucocutaneous telangiectasia and visceral arteriovenous malformations.
- Trial name
- NCT02690246
- Testing
- questionnaire
- Where
- Germany
- Volunteers
- 915 people, healthy volunteers welcome
- Sponsor
- University Hospital, Essen
Hereditary Hemorrhagic Telangiectasia
Anti-Estrogen Therapy for Hereditary Hemorrhagic Telangiectasia A Double-Blind Placebo-Controlled Clinical Trial
Hereditary hemorrhagic telangiectasia (HHT) is associated with recurrent epistaxis in 90% of cases. Good response to hormone treatment has been documented, although its use remains controversial.
- Trial name
- NCT00375622
- Testing
- Tamoxifen
- Where
- Israel
- Volunteers
- 60 people
- Sponsor
- Rabin Medical Center
Hereditary Hemorrhagic Telangiectasia, Osler Weber Rendu Disease
Propranolol for Epistaxis in Hereditary Hemorrhagic Telangiectasia Patients
Hereditary Hemorrhagic Telangiectasia (HHT) is a genetic disorder of angiogenesis associated with disabling epistaxis. Management of these nose bleedings requires more effective treatment.
- Trial name
- EPERO (NCT04113187)
- Testing
- Propranolol treatment
- Where
- France
- Volunteers
- 15 people
- Sponsor
- University Hospital, Bordeaux
Telangiectasia, Hereditary Hemorrhagic
Evaluation of Pazopanib on Bleeding in Subjects With Hereditary Haemorrhagic Telangiectasia
This study will investigate whether pazopanib can reduce epistaxis and improve anaemia in subjects with hereditary haemorrhagic telangiectasia (HHT) at a dose that is well tolerated. The study will have 2 parts.
- Trial name
- NCT02204371
- Testing
- Pazopanib
- Where
- 6 sites in United States, Canada
- Volunteers
- 7 people
- Sponsor
- GlaxoSmithKline